CVRx (NASDAQ:CVRX – Get Free Report) was downgraded by research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Briefing.com reports.
Several other equities analysts have also recently weighed in on CVRX. JPMorgan Chase & Co. raised their price target on shares of CVRx from $31.00 to $36.00 and gave the company an “overweight” rating in a research report on Friday, January 26th. Piper Sandler increased their price target on CVRx from $21.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, January 26th.
Check Out Our Latest Stock Report on CVRx
CVRx Stock Performance
Insider Buying and Selling at CVRx
In other CVRx news, insider Paul Verrastro sold 2,545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total transaction of $55,760.95. Following the completion of the transaction, the insider now owns 2,455 shares in the company, valued at $53,789.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Paul Verrastro sold 2,545 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the transaction, the insider now directly owns 2,455 shares of the company’s stock, valued at approximately $53,789.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of CVRx stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 18.30% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Federated Hermes Inc. purchased a new stake in shares of CVRx in the fourth quarter worth about $102,000. Trexquant Investment LP bought a new position in shares of CVRx in the fourth quarter worth approximately $426,000. Jump Financial LLC bought a new stake in CVRx during the fourth quarter valued at approximately $499,000. Valeo Financial Advisors LLC bought a new stake in CVRx during the first quarter valued at approximately $346,000. Finally, Level Four Advisory Services LLC increased its holdings in shares of CVRx by 6.8% in the 4th quarter. Level Four Advisory Services LLC now owns 28,885 shares of the company’s stock worth $908,000 after buying an additional 1,844 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.
CVRx Company Profile
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
See Also
- Five stocks we like better than CVRx
- Profitably Trade Stocks at 52-Week Highs
- Humana Leaves Shareholders in Limbo on 2025 EPS Guidance
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- IBM Sings the Blues on Mixed Pockets of Strength
- How Investors Can Find the Best Cheap Dividend Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.